These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15338193)

  • 1. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
    Kamath AV; Chong S; Chang M; Marathe PH
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506).
    Qin XL; Bi HC; Wang XD; Li JL; Wang Y; Xue XP; Chen X; Wang CX; Xu le J; Wang YT; Huang M
    Int J Pharm; 2010 Apr; 389(1-2):114-21. PubMed ID: 20097278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
    Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
    Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
    Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
    Lee J; Son J; Rhee SW; Kim DH
    Xenobiotica; 2003 Jul; 33(7):755-65. PubMed ID: 12893524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.
    Prueksaritanont T; DeLuna P; Gorham LM; Ma B; Cohn D; Pang J; Xu X; Leung K; Lin JH
    Drug Metab Dispos; 1998 Jun; 26(6):520-7. PubMed ID: 9616186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents.
    Garner CE; Solon E; Lai CM; Lin J; Luo G; Jones K; Duan J; Decicco CP; Maduskuie T; Mercer SE; Gan LS; Qian M; Prakash S; Shen HS; Lee FW
    Drug Metab Dispos; 2008 Jun; 36(6):1102-10. PubMed ID: 18347085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
    Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Lv T; Zheng YT; Sai Y
    Food Chem Toxicol; 2009 Sep; 47(9):2257-68. PubMed ID: 19524010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate.
    Wacher VJ; Silverman JA; Wong S; Tran-Tau P; Chan AO; Chai A; Yu XQ; O'Mahony D; Ramtoola Z
    J Pharmacol Exp Ther; 2002 Oct; 303(1):308-13. PubMed ID: 12235265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.